oxaliplatin + FOLFIRI + bevacizumab + cetuximab

This regimen is a multi-agent combination therapy used primarily in the treatment of metastatic colorectal cancer. It consists of: - **Oxaliplatin** (a platinum-based chemotherapeutic that forms DNA crosslinks, inhibiting DNA replication and transcription) - **FOLFIRI**, itself a combination of: - Folinic acid (leucovorin), which enhances the effect of fluorouracil - Fluorouracil (5-FU), an antimetabolite that disrupts DNA synthesis - Irinotecan, a topoisomerase I inhibitor that prevents DNA uncoiling and duplication[1][2][3][4][5] - **Bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis - **Cetuximab**, a monoclonal antibody targeting epidermal growth factor receptor (EGFR), blocking downstream signaling involved in cell proliferation This intensive regimen combines cytotoxic chemotherapy with two targeted therapies to maximize anti-tumor activity. It is generally reserved for select patients with advanced or metastatic colorectal cancer, often as part of clinical trials or specific clinical scenarios due to increased toxicity risk and complex management requirements[8].